EcoR1 Capital, LLC sold $6.9M of ADAPY
owner at Adaptimmune Therapeutics PLC. 64,052,538 shares at an average of $0.11, traded Jul 28, 2025, filed Jul 30, 2025.
Score components
- +12Role10% owner
- +25Trade size$6.9M at market
- +10Share of holdings soldSold 39% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -41.0%, 3m -45.0%, 6m -67.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000935836-25-000476, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 28, 2025 | SOpen-market sale Ordinary Sharesindirect: See Note | -33,931,740 | $0.11 | $3.8M | 130,492,680 | Jul 30, 2025 |
| Jul 29, 2025 | SOpen-market sale Ordinary Sharesindirect: See Note | -2,687,460 | $0.10 | $272k | 127,805,220 | Jul 30, 2025 |
| Jul 30, 2025 | SOpen-market sale Ordinary Sharesindirect: See Note | -27,433,338 | $0.10 | $2.8M | 100,371,882 | Jul 30, 2025 |
Related signals
Other insiders at Adaptimmune Therapeutics PLC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | Adaptimmune Therapeutics PLC | Gavin Wood Chief Financial Officer | $950 96,000 shares | -100% | |
| 40Moderate | Adaptimmune Therapeutics PLC | William C Bertrand JR Chief Operating Officer | $2,091 207,000 shares | -17% | |
| 56Moderate | Adaptimmune Therapeutics PLC | Ali Behbahani director | $229k 19,500,000 shares | -100% | |
| 50Moderate | Adaptimmune Therapeutics PLC | Adrian Rawcliffe Chief Executive Officer | $18k 30,601 shares | -41% | |
| 45Moderate | Adaptimmune Therapeutics PLC | William C Bertrand JR Chief Operating Officer | $3,243 5,584 shares | -43% | |
| 40Moderate | Adaptimmune Therapeutics PLC | John Lunger Chief Patient Supply Officer | $3,243 5,584 shares | -43% | |
| 40Moderate | Adaptimmune Therapeutics PLC | Elliot Norry Chief Medical Officer | $3,243 5,584 shares | -43% | |
| 55Moderate | Adaptimmune Therapeutics PLC | William C Bertrand JR Chief Operating Officer | $11k 19,542 shares | -193% | |
| 50Moderate | Adaptimmune Therapeutics PLC | John Lunger Chief Patient Supply Officer | $11k 19,542 shares | -193% | |
| 50Moderate | Adaptimmune Therapeutics PLC | Elliot Norry Chief Medical Officer | $13k 22,195 shares | -219% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.